Key result
BMS-986231 infusion in patients with acute decompensated heart failure reduced pulmonary capillary wedge pressure by a mean of 18% and consistently increased non-invasively measured cardiac index.
Why the study?
Does BMS-986231 improve hemodynamic parameters in hospitalized patients with acute decompensation of chronic heart failure and reduced LVEF?
Does BMS-986231 improve hemodynamic parameters in hospitalized patients with acute decompensation of chronic heart failure and reduced LVEF?
Answers are grounded in this paper and cite their sources.
BMS-986231, a novel nitroxyl donor, demonstrated favorable hemodynamic effects including reduced pulmonary capillary wedge pressure and increased cardiac index without detrimental heart rate increases in patients with acute decompensated heart failure.
This article refers to ‘A Phase 2a dose-escalation study of the safety, tolerability, pharmacokinetics, and haemodynamic effects of BMS-986231 in hospitalized patients with heart failure with reduced ejection fraction’ by C. Tita et al., published in this issue on pages 1321–1332. Acute heart failure (AHF) constitutes a heterogeneous clinical syndrome, which remains a significant challenge for everyday clinical practice, clinical research, and drug development. From the clinical perspective, AHF is characterized by high mortality rates reaching 30% within 1 year following the acute event and the increased need for repeated hospitalizations (20% within 30 days and 50% within 6 months).1 Currently available treatment modalities for AHF offer symptomatic relief in a substantial number of cases, but have failed to improve short and long term outcomes.2 Meanwhile, advances in therapeutic management of AHF have been extremely limited, with several new molecules failing to result in meaningful clinical benefits. Possible reasons for these treatment failures include diverse syndrome pathophysiology [patients with acute decompensation of chronic heart failure (ADCHF) or de novo heart failure with preserved or reduced left ventricular ejection fraction (LVEF)], heterogeneity in patient demographic and clinical characteristics, and inappropriate therapeutic targets/molecules or trial design.3 Regardless of the specific underlying pathophysiology, common contributors to AHF development include impaired cardiac mechanics, cardiac injury, vasoconstriction, endothelial dysfunction, excess neurohormonal activation, and renal dysfunction.4 Clinical manifestations in this setting are predominantly due to a combination of reduced cardiac output, increased left and right heart pressures, and systemic (venous and arterial) vasoconstriction, causing cardiac overload and venous congestion. Although AHF phenotypes share common pathophysiological pathways, the individual contribution of these pathways and the complex interplays among them result in diverse AHF phenotypes, requiring individualized management. In this regard, ADCHF with preserved or reduced LVEF is observed as part of the natural course of the syndrome, may develop during early or advanced clinical stages in patients receiving or not neurohormonal antagonists, and may be precipitated by specific factors (i.e. infection, uncontrolled hypertension, non-adherence to drugs or diet). Unfortunately, treatment is usually empirical and in most cases includes diuretics with or without vasodilators following the ‘one size fits all’ model. The situation is slightly different in de novo AHF, which is frequently precipitated by an acute ischaemic, arrhythmic, inflammatory or mechanical cardiac event. In this setting, diuretics and vasodilators usually supplement the eradication of the underlying cause. In any case, individualized, phenotype-based management should be pursued in all patients with AHF.5 In this issue of the European Journal of Heart Failure, Tita et al.6 present the results of a phase 2a study of a novel molecule, BMS-986231, given in a specific AHF patient subgroup comprising patients with ADCHF and reduced LVEF. BMS-986231 is a second-generation nitroxyl donor that releases HNO, a molecule shown in pre-clinical studies to produce a variety of beneficial effects on cardiac function, including enhancement of inotropy, lusitropy, and vasodilation.7 Inotropic and lusitropic effects are mediated through the post-translational modification of calcium-regulating cardiomyocyte proteins, including SERCA-2a, phospholamban and ryanodine receptors, while arterial and venous vasodilation have been attributed to the activation of soluble guanylate cyclase.8, 9 Meanwhile, BMS-986231 does not affect L-type calcium channel current or total sarcoplasmic reticulum calcium load, an unwanted effect caused by traditional inotropic agents that has been associated with arrhythmogenesis. The study by Tita et al. is a dose–response study, designed to test the safety, tolerability, and haemodynamic effects of BMS-986231 (n = 46). Four sequentially escalated drug-dosing schemes (3, 5, 7, or 12 µg/kg/min) were administered in four patient groups and compared against placebo. Study results with respect to the haemodynamic effects of the active comparator confirm the beneficial haemodynamic effects of BMS-986231 in the clinical setting of ADCHF, which resulted in unloading of the left and possibly the right ventricle. BMS-986231 reduced pulmonary capillary wedge pressure by a mean of 18% across all dosing groups throughout the duration of the 6 h infusion, and similar reductions were detected in pulmonary artery systolic and diastolic pressures, and in high doses for right atrial pressure. Moreover, although the cardiac index (CI) measured by the Fick method (primary end-point) did not show a clear pattern of effect, non-invasively measured CI was consistently increased by all dosing schemes of BMS-986231, significance achieved by the two highest dose regimens. Additionally, systemic vascular resistance was reduced by the active drug, and, as expected, arterial systolic and diastolic blood pressure were also reduced. However, the most prominent increase of CI produced by the highest dosing scheme of the active drug (12 µg/kg/min) counteracted the effects of systemic vasodilation on systolic blood pressure, which did not actually decrease in this dosing regimen. A limitation of this study is that the potential direct effects of BMS-986231 on cardiac function were not assessed. It is not known, therefore, whether the improved haemodynamic patient profile was due to vasodilation per se or vasodilation acting on top of the potential positive inotropic and/or lusitropic effects of the drug. However, this study has re-confirmed the favourable haemodynamic, tolerability, and safety profile of BMS-986231. Regarding safety, the neutral effect of the active drug on the heart rate, which contrasts with the detrimental increase in heart rate caused by most of the conventional inotropic agents, justifies the optimism that a non-arrhythmogenic profile will be revealed in future large-scale testing. The latter is also required to acquire data regarding the effect of BMS-986231 on markers of myocardial injury (i.e. troponins), also increased by the currently used conventional inotropic agents. Overall, these preliminary findings regarding the use of BMS-986231 in patients with ADCHF and reduced LVEF are encouraging. Therefore, further large-scale testing is strongly encouraged to assess the effect of this drug on outcomes in this patient population.
No takes yet. Share an insight, caveat, or question.
Parissis et al. (2017) conducted an editorial in Acute decompensation of chronic heart failure (ADCHF) with reduced LVEF (n=46). BMS-986231 vs. Placebo was evaluated on Cardiac index (CI) measured by the Fick method. BMS-986231 infusion in patients with acute decompensated heart failure reduced pulmonary capillary wedge pressure by a mean of 18% and consistently increased non-invasively measured cardiac index.
Synapse has enriched 10 related papers. Consider them for comparative context: